Plaintiffs in Zantac Lawsuits Employ Unconsolidated Strategy to Protect Individual Outcomes in Connecticut Courts

In an evolving litigation strategy, plaintiffs in nine separate cases against major pharmaceutical companies over alleged Zantac injuries are opting to keep their claims unconsolidated within Connecticut state court by naming fewer than 100 people per case. This tactic has been designed to prevent the cases from being grouped into a single trial, which could potentially compromise individual outcomes. The approach yielded a significant outcome for the 853 plaintiffs when the U.S. Court of Appeals for the Second Circuit upheld their motion to consolidate for pretrial purposes only, affirming that the plaintiffs did not intend to seek a joint trial. For further details, the original article can be found on Law.com.